Pacific Biosciences
PACB
215 hedge funds and large institutions have $374M invested in Pacific Biosciences in 2025 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 69 increasing their positions, 49 reducing their positions, and 32 closing their positions.
303% more call options, than puts
Call options by funds: $7.02M | Put options by funds: $1.74M
57% more capital invested
Capital invested by funds: $238M → $374M (+$136M)
41% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 49
34% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 32
4.49% more ownership
Funds ownership: 62% → 66.49% (+4.5%)
3% more funds holding
Funds holding: 208 → 215 (+7)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$12.2M |
| 2 |
D.E. Shaw & Co
New York
|
+$8.53M |
| 3 |
Renaissance Technologies
New York
|
+$7.4M |
| 4 |
CC
Casdin Capital
New York
|
+$6.73M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$13.7M |
| 2 |
MA
Madrone Advisors
Menlo Park,
California
|
-$6.37M |
| 3 |
PEAK6
Chicago,
Illinois
|
-$1.71M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
-$1.67M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$1.67M |
PACB Hedge Fund Activity: Q4 2025 in Review
215 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2025, worth a combined $374M — up 57% from $238M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new PACB positions and 32 closed out — a net gain of 11 holders — while 69 added to existing stakes and 49 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $12.2M. The largest seller was Edmond de Rothschild Holding, exiting entirely with an estimated $13.7M sold.
- 215 institutional investors held Pacific Biosciences (PACB) as of Q4 2025, up from 208 in Q3 2025.
- Funds reported $374M of Pacific Biosciences stock for Q4 2025, up 57% quarter-over-quarter.
- 43 funds opened new Pacific Biosciences positions in Q4 2025 and 32 closed out, a net change of +11 holders.
- The largest Pacific Biosciences buyer in Q4 2025 was ARK Investment Management, an estimated $12.2M added.
- The largest Pacific Biosciences seller in Q4 2025 was Edmond de Rothschild Holding, an estimated $13.7M sold.
Based on aggregated 13F filings for Q4 2025.